Literature DB >> 3189368

Clinically significant valvular heart disease in systemic lupus erythematosus.

K V Straaton1, W W Chatham, J D Reveille, W J Koopman, S H Smith.   

Abstract

PURPOSE: Clinically significant valvular heart disease due to systemic lupus erythematosus (SLE) has generally been considered rare, and Libman-Sacks endocarditis has been thought to be predominantly an autopsy finding. With the declining prevalence of rheumatic heart disease, however, the spectrum of valvular heart disease is changing. We retrospectively analyzed our experience with SLE between 1975 and 1987 for the presence of hemodynamically significant valvular heart disease. PATIENTS AND METHODS: An existing data base of 421 patients with SLE was selected for review. Patients were selected for inclusion in the study if they met four or more of the criteria of the American Rheumatism Association for SLE, they had clinically significant valvular heart disease, and tissue from the involved valve was available for review. The etiology of the valve lesion was determined by assessment of the clinical history, chart review, gross morphology, and valve histology.
RESULTS: Of 14 cases with pathologic material available for review, six had anatomic features of SLE valvular heart disease such as verrucous vegetations or valvulitis with necrosis and vasculitis. Two of these patients underwent successful valve replacements and four died from complications of their valve disease.
CONCLUSION: We suggest that significant morbidity and mortality may result from SLE valvular heart disease in about 1 to 2 percent of SLE patients and that the pathogenetic mechanisms underlying valve dysfunction in SLE patients are multifactorial.

Entities:  

Mesh:

Year:  1988        PMID: 3189368     DOI: 10.1016/s0002-9343(88)80236-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Cardiac valvulopathy in the antiphospholipid syndrome.

Authors:  Shaul Lev; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

2.  Heart valve disease in systemic lupus erythematosus. Role of antiphospholipid antibodies.

Authors:  O Meyer; M Golstein; P Nicaise; C Labarre; M F Kahn
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  Infective endocarditis, rheumatoid factor, and anticardiolipin antibodies.

Authors:  R A Asherson; M Tikly; H Staub; P T Wilmshurst; D J Coltart; M Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

4.  Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients.

Authors:  R Cervera; J Font; C Paré; M Azqueta; F Pérez-Villa; A López-Soto; M Ingelmo
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

5.  Cardiovascular Complications of Collagen Vascular Disease.

Authors:  Gary E. Sander; Thomas D. Giles
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-04

Review 6.  Mitral valve replacement and repair. Report of 5 patients with systemic lupus erythematosus.

Authors:  J P Hakim; A Mehta; A C Jain; G F Murray
Journal:  Tex Heart Inst J       Date:  2001

7.  Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis?

Authors:  David Armstrong; Stephen Wright; Claire McVeigh; Michael Finch
Journal:  Clin Rheumatol       Date:  2005-10-13       Impact factor: 2.980

8.  Systemic lupus erythematosus complicated by tricuspid stenosis and regurgitation: successful treatment by valve transplantation.

Authors:  D E Ames; R A Asherson; J D Coltart; V Vassilikos; J K Jones; G R Hughes
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

Review 9.  Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature.

Authors:  Wobbe Bouma; Theo J Klinkenberg; Iwan C C van der Horst; Inez J Wijdh-den Hamer; Michiel E Erasmus; Marc Bijl; Albert J H Suurmeijer; Felix Zijlstra; Massimo A Mariani
Journal:  J Cardiothorac Surg       Date:  2010-03-23       Impact factor: 1.637

10.  Anti-nuclear antibodies positive serum from systemic lupus erythematosus patients promotes cardiovascular manifestations and the presence of human antibody in the brain.

Authors:  Marie Kelly-Worden; Leslie Hammer; Robyn Gebhard; Lauran Schrader; Marley Griffin; Dalahnna Cooper
Journal:  J Pharm Bioallied Sci       Date:  2014-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.